Correction: Sequential HER2 blockade as effective therapy in chemorefractory, HER2 gene-amplified, RAS wild-type, metastatic colorectal cancer: learning from a clinical case
| Main Authors: | , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2019-04-01
|
| Series: | ESMO Open |
| Online Access: | https://esmoopen.bmj.com/content/4/2/e000299corr1.full |
| _version_ | 1818779091365527552 |
|---|---|
| author | Matteo Fassan Chiara Cremolini Matteo Benelli Elisa Fontana Filippo Pagani Daniele Rossini Giovanni Fucà Adele Busico Elena Conca Samantha Di Donato Fotios Loupakis Marta Schirripa Sara Lonardi Beatrice Borelli Elena Ongaro Katherine Eason Mariaelena Casagrande Anguraj Sadanandam Filippo de Braud Alfredo Falcone |
| author_facet | Matteo Fassan Chiara Cremolini Matteo Benelli Elisa Fontana Filippo Pagani Daniele Rossini Giovanni Fucà Adele Busico Elena Conca Samantha Di Donato Fotios Loupakis Marta Schirripa Sara Lonardi Beatrice Borelli Elena Ongaro Katherine Eason Mariaelena Casagrande Anguraj Sadanandam Filippo de Braud Alfredo Falcone |
| author_sort | Matteo Fassan |
| collection | DOAJ |
| first_indexed | 2024-12-18T11:55:06Z |
| format | Article |
| id | doaj.art-1d07beac33804ab2aa944b45e0bdd34e |
| institution | Directory Open Access Journal |
| issn | 2059-7029 |
| language | English |
| last_indexed | 2024-12-18T11:55:06Z |
| publishDate | 2019-04-01 |
| publisher | Elsevier |
| record_format | Article |
| series | ESMO Open |
| spelling | doaj.art-1d07beac33804ab2aa944b45e0bdd34e2022-12-21T21:09:05ZengElsevierESMO Open2059-70292019-04-014210.1136/esmoopen-2017-000299corr1Correction: Sequential HER2 blockade as effective therapy in chemorefractory, HER2 gene-amplified, RAS wild-type, metastatic colorectal cancer: learning from a clinical caseMatteo Fassan0Chiara Cremolini1Matteo Benelli2Elisa Fontana3Filippo Pagani4Daniele Rossini5Giovanni Fucà6Adele Busico7Elena Conca8Samantha Di Donato9Fotios Loupakis10Marta Schirripa11Sara Lonardi12Beatrice Borelli13Elena Ongaro14Katherine Eason15Mariaelena Casagrande16Anguraj Sadanandam17Filippo de Braud18Alfredo Falcone19Department of Medicine (DIMED), University of Padua, Padova, ItalyDepartment of Translational Medicine, Division of Medical Oncology, University of Pisa, Pisa, Italy3 Bioinformatics Unit, Oncology Department, Hospital of Prato, Prato, ItalyMolecular Pathology, The Institute of Cancer Research, Sutton, UK6 Medical Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy 1 Unit of Medical Oncology 2, Azienda Ospedaliero Universitaria Pisana, Pisa, Italy 6 Medical Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy7 Department of Diagnostic Pathology and Laboratory Medicine, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy7 Department of Diagnostic Pathology and Laboratory Medicine, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy8 Medical Oncology Unit, Oncology Department, Hospital of Prato, Prato, ItalyClinical and Experimental Oncology Department, Medical Oncology Unit 1, Veneto Institute of Oncology IOV-IRCCS, Padua, Italy9 Unit of Medical Oncology 1, Department of Clinical and Experimental Oncology, IRCCS Istituto Oncologico Veneto, Padova, Italy9 Unit of Medical Oncology 1, Department of Clinical and Experimental Oncology, IRCCS Istituto Oncologico Veneto, Padova, Italy1 Unit of Medical Oncology 2, Azienda Ospedaliero Universitaria Pisana, Pisa, Italy 1 Unit of Medical Oncology 2, Azienda Ospedaliero Universitaria Pisana, Pisa, Italy 4 Division of Molecular Pathology, The Institute of Cancer Research, London, UK10 Department of Oncology, Azienda Sanitaria Universitaria Integrata di Udine, Udine, Italy4 Division of Molecular Pathology, The Institute of Cancer Research, London, UK 6 Medical Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy Department of Translational Medicine, Division of Medical Oncology, University of Pisa, Pisa, Italyhttps://esmoopen.bmj.com/content/4/2/e000299corr1.full |
| spellingShingle | Matteo Fassan Chiara Cremolini Matteo Benelli Elisa Fontana Filippo Pagani Daniele Rossini Giovanni Fucà Adele Busico Elena Conca Samantha Di Donato Fotios Loupakis Marta Schirripa Sara Lonardi Beatrice Borelli Elena Ongaro Katherine Eason Mariaelena Casagrande Anguraj Sadanandam Filippo de Braud Alfredo Falcone Correction: Sequential HER2 blockade as effective therapy in chemorefractory, HER2 gene-amplified, RAS wild-type, metastatic colorectal cancer: learning from a clinical case ESMO Open |
| title | Correction: Sequential HER2 blockade as effective therapy in chemorefractory, HER2 gene-amplified, RAS wild-type, metastatic colorectal cancer: learning from a clinical case |
| title_full | Correction: Sequential HER2 blockade as effective therapy in chemorefractory, HER2 gene-amplified, RAS wild-type, metastatic colorectal cancer: learning from a clinical case |
| title_fullStr | Correction: Sequential HER2 blockade as effective therapy in chemorefractory, HER2 gene-amplified, RAS wild-type, metastatic colorectal cancer: learning from a clinical case |
| title_full_unstemmed | Correction: Sequential HER2 blockade as effective therapy in chemorefractory, HER2 gene-amplified, RAS wild-type, metastatic colorectal cancer: learning from a clinical case |
| title_short | Correction: Sequential HER2 blockade as effective therapy in chemorefractory, HER2 gene-amplified, RAS wild-type, metastatic colorectal cancer: learning from a clinical case |
| title_sort | correction sequential her2 blockade as effective therapy in chemorefractory her2 gene amplified ras wild type metastatic colorectal cancer learning from a clinical case |
| url | https://esmoopen.bmj.com/content/4/2/e000299corr1.full |
| work_keys_str_mv | AT matteofassan correctionsequentialher2blockadeaseffectivetherapyinchemorefractoryher2geneamplifiedraswildtypemetastaticcolorectalcancerlearningfromaclinicalcase AT chiaracremolini correctionsequentialher2blockadeaseffectivetherapyinchemorefractoryher2geneamplifiedraswildtypemetastaticcolorectalcancerlearningfromaclinicalcase AT matteobenelli correctionsequentialher2blockadeaseffectivetherapyinchemorefractoryher2geneamplifiedraswildtypemetastaticcolorectalcancerlearningfromaclinicalcase AT elisafontana correctionsequentialher2blockadeaseffectivetherapyinchemorefractoryher2geneamplifiedraswildtypemetastaticcolorectalcancerlearningfromaclinicalcase AT filippopagani correctionsequentialher2blockadeaseffectivetherapyinchemorefractoryher2geneamplifiedraswildtypemetastaticcolorectalcancerlearningfromaclinicalcase AT danielerossini correctionsequentialher2blockadeaseffectivetherapyinchemorefractoryher2geneamplifiedraswildtypemetastaticcolorectalcancerlearningfromaclinicalcase AT giovannifuca correctionsequentialher2blockadeaseffectivetherapyinchemorefractoryher2geneamplifiedraswildtypemetastaticcolorectalcancerlearningfromaclinicalcase AT adelebusico correctionsequentialher2blockadeaseffectivetherapyinchemorefractoryher2geneamplifiedraswildtypemetastaticcolorectalcancerlearningfromaclinicalcase AT elenaconca correctionsequentialher2blockadeaseffectivetherapyinchemorefractoryher2geneamplifiedraswildtypemetastaticcolorectalcancerlearningfromaclinicalcase AT samanthadidonato correctionsequentialher2blockadeaseffectivetherapyinchemorefractoryher2geneamplifiedraswildtypemetastaticcolorectalcancerlearningfromaclinicalcase AT fotiosloupakis correctionsequentialher2blockadeaseffectivetherapyinchemorefractoryher2geneamplifiedraswildtypemetastaticcolorectalcancerlearningfromaclinicalcase AT martaschirripa correctionsequentialher2blockadeaseffectivetherapyinchemorefractoryher2geneamplifiedraswildtypemetastaticcolorectalcancerlearningfromaclinicalcase AT saralonardi correctionsequentialher2blockadeaseffectivetherapyinchemorefractoryher2geneamplifiedraswildtypemetastaticcolorectalcancerlearningfromaclinicalcase AT beatriceborelli correctionsequentialher2blockadeaseffectivetherapyinchemorefractoryher2geneamplifiedraswildtypemetastaticcolorectalcancerlearningfromaclinicalcase AT elenaongaro correctionsequentialher2blockadeaseffectivetherapyinchemorefractoryher2geneamplifiedraswildtypemetastaticcolorectalcancerlearningfromaclinicalcase AT katherineeason correctionsequentialher2blockadeaseffectivetherapyinchemorefractoryher2geneamplifiedraswildtypemetastaticcolorectalcancerlearningfromaclinicalcase AT mariaelenacasagrande correctionsequentialher2blockadeaseffectivetherapyinchemorefractoryher2geneamplifiedraswildtypemetastaticcolorectalcancerlearningfromaclinicalcase AT angurajsadanandam correctionsequentialher2blockadeaseffectivetherapyinchemorefractoryher2geneamplifiedraswildtypemetastaticcolorectalcancerlearningfromaclinicalcase AT filippodebraud correctionsequentialher2blockadeaseffectivetherapyinchemorefractoryher2geneamplifiedraswildtypemetastaticcolorectalcancerlearningfromaclinicalcase AT alfredofalcone correctionsequentialher2blockadeaseffectivetherapyinchemorefractoryher2geneamplifiedraswildtypemetastaticcolorectalcancerlearningfromaclinicalcase |